Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).
*The following content is generated by AI and is for reference only.
Overview
Pharmaceutical Grade Dotinurad is a potent uricosuric agent used for chronic gout management. Synthesized via advanced organic processes, it inhibits URAT1 to enhance renal urate excretion. The compound features the molecular formula C20H18N4O3 and CAS number 1365793-34-9.
Application
- Manufacture of oral tablets for hyperuricemia treatment.
- R&D of novel formulations targeting refractory gout patients.
- Quality control standards for pharmaceutical API supply chains.
Precautions
Strictly contraindicated in patients with severe renal impairment or active kidney stones. Storage requires dry conditions below 25°C away from direct sunlight to maintain stability. Personal protective equipment is mandatory during handling to prevent dermal absorption.